Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1990 1
1994 1
2000 1
2003 1
2004 1
2006 1
2008 3
2009 1
2011 3
2012 3
2013 2
2016 1
2018 1
2019 1
2020 1
2021 6
2022 2
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
[Advanced Adenocarcinoma of the Bladder after Augmentation Gastrocystoplasty].
Kono Y, Terada N, Takashima Y, Hikami K, Hida T, Goto S, Sunada T, Okada Y, Shibasaki N, Negoro H, Kobayashi T, Yamasaki T, Matsui Y, Inoue T, Kamba T, Ogawa O. Kono Y, et al. Among authors: hikami k. Hinyokika Kiyo. 2016 Jan;62(1):33-7. Hinyokika Kiyo. 2016. PMID: 26932334 Free article. Review. Japanese.
Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction.
Kita Y, Ito K, Kanda S, Joraku A, Yamaguchi R, Shimizu Y, Hayata N, Somiya S, Shibasaki N, Kimura T, Hikami K, Yamada T, Abe T, Tsuchihashi K, Tatarano S, Nishiyama H, Kitamura H, Kobayashi T. Kita Y, et al. Among authors: hikami k. Urol Oncol. 2022 Sep;40(9):410.e11-410.e18. doi: 10.1016/j.urolonc.2022.04.005. Epub 2022 May 9. Urol Oncol. 2022. PMID: 35551861
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group. Kobayashi M, et al. BJU Int. 2022 Aug;130(2):226-234. doi: 10.1111/bju.15510. Epub 2021 Jul 6. BJU Int. 2022. PMID: 34110696
Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis.
Hikami K, Ehara Y, Hasegawa M, Fujimoto M, Matsushita M, Oka T, Takehara K, Sato S, Tokunaga K, Tsuchiya N. Hikami K, et al. Biochem Biophys Res Commun. 2008 Aug 29;373(3):403-7. doi: 10.1016/j.bbrc.2008.06.054. Epub 2008 Jun 25. Biochem Biophys Res Commun. 2008. PMID: 18588853
Molecular genetic analyses of human NKG2C (KLRC2) gene deletion.
Miyashita R, Tsuchiya N, Hikami K, Kuroki K, Fukazawa T, Bijl M, Kallenberg CG, Hashimoto H, Yabe T, Tokunaga K. Miyashita R, et al. Among authors: hikami k. Int Immunol. 2004 Jan;16(1):163-8. doi: 10.1093/intimm/dxh013. Int Immunol. 2004. PMID: 14688071
Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Osaki Y, Tashiro Y, Uegaki M, Ogawa O, Kitamura H, Nishiyama H. Ito K, et al. Among authors: hikami k. Cancer Med. 2021 May;10(10):3188-3196. doi: 10.1002/cam4.3863. Epub 2021 May 1. Cancer Med. 2021. PMID: 33931987 Free PMC article.
28 results